Last updated: May 19, 2026
MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER (cefoxitin) Clinical Trials Update, Market Analysis, and U.S. Projection
Mefoxin in Dextrose 5% in plastic container is the IV cefoxitin combination product delivering cefoxitin in a 5% dextrose diluent. It remains a niche injectable antibiotic product in the U.S. market with limited publicly traceable late-stage development activity. Market performance is driven by hospital inpatient antibiotic formularies, competitive generics/authorized product swaps, antimicrobial stewardship cycles, and periodic supply and procurement shifts rather than consumer demand. Public clinical-trial signals tied to this specific finished product are sparse; any clinical activity is more likely attributable to cefoxitin class research or comparative antibiotic studies, not new label expansions for this exact presentation.
What clinical trials exist for MEFOXIN (cefoxitin) in dextrose 5% IV plastic container?
Answer: Public clinical-trial activity specifically for “Mefoxin in Dextrose 5% in plastic container” is not meaningfully visible as distinct late-stage registrational development. The observable clinical evidence base for cefoxitin typically comes from earlier trials supporting antibacterial efficacy and spectrum, plus post-marketing and comparative studies for cephalosporins.
How to interpret “this exact container” in trial discovery
- Regulatory trials and labeling are generally tied to the active ingredient (cefoxitin) and dosage form (IV), not to the exact packaging substrate once it is within standard manufacturing controls.
- Packaging (“plastic container,” “dextrose 5%”) often changes from one manufacturer to another, and it is rarely the unit of clinical development.
Typical trial patterns you would expect (but that are not clearly product-specific)
- Comparative trials versus other beta-lactams for susceptible infections (intra-abdominal, gynecologic, skin/soft tissue where cefoxitin historically fits).
- Clinical endpoint-driven studies for microbiologic eradication and clinical response.
- Safety/PK work is more common earlier in lifecycle; late-stage trials for older antibiotics often focus on stewardship-era comparative effectiveness or new combinations, not a new container.
What is the current clinical pipeline risk for cefoxitin (MEFOXIN) IV products?
Answer: Pipeline risk is low in the sense that cefoxitin is not widely characterized as an actively expanding development franchise. The main risk is commercial and supply continuity rather than investigational failure.
Key risk drivers affecting future use
- Antimicrobial stewardship and guideline positioning: cefoxitin usage can shift based on empiric therapy recommendations and local antibiogram resistance trends.
- Resistance evolution: cefoxitin susceptibility depends on community and hospital Gram-negative and anaerobe profiles.
- Substitution pressure: newer broad-spectrum agents (and other cef/β-lactam combinations) can displace older cephamycins where clinical distinctions are marginal.
- Supply and manufacturing continuity: IV antibiotic shortages and reallocation patterns can affect short-term utilization.
How big is the market for IV cefoxitin and where does “dextrose 5% in plastic container” fit?
Answer: Cefoxitin is a concentrated hospital injectable market segment rather than a consumer-facing product category. The “Mefoxin” branded presentation competes with multiple generic cefoxitin sodium injectables; the dextrose 5% diluent and plastic container influence tendering and stocking compatibility.
Market structure for hospital IV antibiotics
- Buyers: GPOs, hospital pharmacy procurement, wholesaler formularies, ID stewardship committees.
- Decision factors: acquisition cost, availability, dosing convenience, compatibility with IV workflows, and formulary tiering.
- Substitution: if generics are available, branded share typically declines unless price parity or supply assurance shifts the balance.
What governs brand vs generic share
- Contract tender cycles: antibiotics are often bought through bid awards where packaging and stability documentation matter.
- Stocking policies: hospitals may standardize on particular diluents/container types.
- Supply continuity: if branded product availability is more reliable during shortages, branded share can temporarily rise.
Who are the competing products and what does substitution look like versus MEFOXIN in D5W?
Answer: The competitive set is primarily other cefoxitin sodium IV formulations and competing beta-lactam antibiotic options used for similar infection categories.
Direct competitive set (same active, different generics and presentations)
- Generic cefoxitin sodium IV products in various vial strengths and diluent configurations.
- Authorized generics or different packaged formats (vial vs plastic container) that meet pharmacy compounding and compatibility requirements.
Indirect therapeutic substitutes
- Other cephalosporins with broader or more stewardship-aligned coverage in hospital formularies.
- Beta-lactam/beta-lactamase inhibitor regimens for intra-abdominal and complicated infection pathways.
- Carbapenems reserved for higher resistance risk; their use can displace older cephamycins in some hospitals.
When does MEFOXIN (cefoxitin) lose exclusivity, and what patents matter commercially?
Answer: For a mature generic-exposed antibiotic like cefoxitin, exclusivity and patent barriers are typically already cleared or near-expired for branded finished products. For this specific finished product presentation, the actionable risk is less “exclusivity timing” and more whether any formulation/manufacturing patents remain in force for the packaged-dextrose configuration.
What to check in Orange Book style frameworks (for action)
Even when clinical development is limited, exclusivity and patent status still determine whether branded tendering advantages persist. The main commercial determinants are:
- Listed patents covering composition or formulation for the finished dose and container/diluent system.
- Any method-of-manufacture patents affecting plastic container and solution characteristics.
- Any remaining exclusivity tied to changes in formulation or manufacturing process (rare for older products).
(No Orange Book listing data was provided in the prompt, so no specific patent numbers or expiration dates are included here.)
What is the Orange Book status of MEFOXIN in Dextrose 5% in plastic container?
Answer: Not provided in the prompt, and no reliable listing can be stated without pulling the specific FDA Orange Book entry for the exact NDA/strength/package combination. For decision-making, the correct field to extract is the “Dosage Form/Route + Package” mapping to the exact dextrose-plastic configuration.
What generic entry risks exist for cefoxitin D5W plastic container?
Answer: Generic entry risk is structurally high in mature injectable antibiotics because multiple manufacturers can qualify cefoxitin and package formats if they can meet FDA product requirements and manufacturing controls. The remaining risk is not clinical efficacy but regulatory and supply execution.
Generic entry scenarios that typically matter
- New ANDA approvals for cefoxitin sodium packaged in D5W plastic container format.
- Manufacturer switching in tender cycles where the hospital is indifferent to brand if supply and price align.
- Competitive reallocation during shortages affecting branded availability and market share.
(No product-specific patent/ANDA Paragraph IV data was provided in the prompt, so no litigation-based risk timing is stated.)
What patent litigation affects MEFOXIN or cefoxitin IV products?
Answer: Not provided in the prompt. Cefoxitin’s long lifecycle usually means that if litigation exists, it is older and does not materially affect near-term commercialization. Without the case list or FDA/Orange Book patent-to-litigation mapping, no specific litigation impact can be stated.
What formulation patents protect cefoxitin in dextrose 5% plastic containers?
Answer: Not provided in the prompt; no formulation patent set can be listed without a patent landscape pull tied to the exact finished dosage form.
What formulation patents would typically cover (if any are still active)
- Chemical stability in D5W (shelf-life, impurity profile)
- Container-closure interaction and extractables/leachables
- pH/spec limits that ensure compatibility with plastic container
- Manufacturing process controls that are protected as specific steps rather than the base drug
How strong is the patent estate for MEFOXIN (cefoxitin) finished IV presentations?
Answer: For mature antibiotics, the practical patent estate strength is usually low because composition-of-matter and early process patents expire years earlier. The remaining protected space is limited to late-life formulation/manufacturing improvements. This presentation-specific strength cannot be quantified without the exact Orange Book patent list.
What is the FDA regulatory status and what pathway governs MEFOXIN in D5W plastic container?
Answer: The prompt does not provide the NDA/ANDA identifiers, so the exact regulatory status cannot be stated. For older branded IV antibiotics, the regulatory “market availability” is typically maintained via an existing NDA and generic competition via ANDAs.
What regulators usually require for this product category
- Sterility assurance and endotoxin control
- Stability in D5W and compatibility with container system
- Quality controls for cefoxitin impurity profile
- Packaging integrity and labeled storage conditions
Market projection: how will MEFOXIN D5W plastic container perform over 3–5 years?
Answer: Without brand revenue and without FDA/Orange Book/ANDA timing data tied to this exact presentation, only a scenario-appropriate directional projection is possible. The base case for mature IV antibiotics is continued pressure from generics, with modest volatility driven by procurement cycles and supply availability.
Projection logic for mature injectable antibiotics
- Volume trend: typically down or flat versus earlier years once generics establish stable coverage.
- Price trend: downward versus branded list prices after contracting and generic benchmarking.
- Market share: brand share stabilizes when supply assurance, contract pricing, and tender alignment favor incumbents.
- Competitive shocks: temporary increases can occur during shortages in the generic segment.
Practical 3–5 year outlook (directional)
- Base case: steady-to-declining unit share for branded “Mefoxin” against generic cefoxitin packaged alternatives.
- Upside: if procurement contracts prioritize this specific presentation due to availability or compatibility requirements.
- Downside: if competing packaged formats win repeat tenders at lower cost or if stewardship shifts reduce cefoxitin utilization for common empiric regimens.
(No unit sales, WAC/NADAC history, or contract pricing was provided, so no numeric forecast can be produced.)
Commercial impact by stakeholder: what matters for hospital buyers, payers, and manufacturers?
Answer: Buyers care about total procurement cost plus reliability; manufacturers care about tender-driven volume and manufacturing continuity.
For hospital procurement
- Seek best total cost across contracted tender windows.
- Reduce stockouts risk by maintaining multiple sources if feasible.
- Validate compatibility with current pharmacy workflows and line configurations.
For brand/manufacturer strategy
- Focus on contract retention, supply assurance, and packaging compatibility documentation.
- Defend share where procurement prefers consistent lead times or specific diluent/container.
Key Takeaways
- “Mefoxin in Dextrose 5% in plastic container” is a mature IV cefoxitin presentation with limited visible product-specific late-stage clinical development.
- Market dynamics are procurement- and supply-driven in hospital settings, with ongoing substitution pressure from generics.
- Patent and exclusivity determinations for the exact finished presentation cannot be stated without the specific Orange Book entry and associated patent list; in mature antibiotic categories, remaining barriers are usually formulation/manufacturing-specific and narrow.
- 3–5 year performance is most likely characterized by gradual brand share erosion versus generics, with short-term volatility tied to availability and contracting.
FAQs
- Is cefoxitin still recommended for intra-abdominal infections in current hospital formularies?
- Does packaging in D5W vs vial format change clinical outcomes or only pharmacy logistics?
- How do antibiotic shortages typically shift market share between branded Mefoxin and generic cefoxitin?
- What does procurement typically require for cefoxitin IV tendering (stability, container closure documentation, lead time)?
- Do any current Orange Book patents meaningfully affect generic entry for cefoxitin D5W plastic container products?
References (APA)
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- ClinicalTrials.gov. U.S. National Library of Medicine.
- PubMed. U.S. National Library of Medicine.
